Research programme: B-cell specific cancer therapeutics - Larkspur Biosciences
Latest Information Update: 29 Aug 2023
At a glance
- Originator Larkspur Biosciences
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Phosphatidylserine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer